Suggested remit: To appraise the clinical and cost effectiveness of vosoritide within its marketing authorisation for treating achondroplasia in children and young people under 18 years.
- Status:
- Awaiting development
- Decision:
- None selected
- Process:
- TA
- ID number:
- 3807
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 30 October 2024 | Note - Note added to the project documents |
| 24 November 2020 | Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual